SCIENCE AND pipeline

science and pipeline

PIPELINE OVERVIEW

Using our Symphony™ platform, Aria has developed a pipeline of promising treatments in over a dozen programs across a range of therapeutic areas.  All our candidates have novel mechanisms of action that have shown statistically significant efficacy in preclinical studies. But that’s just the beginning. We have the power to apply our science in 1000+ complex diseases.

Aria Pipeline

ABOUT SYMPHONY

Symphony™ is Aria’s proprietary drug-discovery AI-platform that decodes complex biology problems to find novel ways of targeting challenging diseases with greater speed and a higher rate of certainty than traditional drug discovery processes.

ABOUT SYMPHONY

Symphony™ is Aria’s proprietary drug-discovery AI-platform that decodes complex biology problems to find novel ways of targeting challenging diseases with greater speed and a higher rate of certainty than traditional drug discovery processes.

PUBLICATIONS & POSTERS

Leveraging Artificial Intelligence to Identify Drug Leads & Establish Safety & Efficacy from Human Derived Data

Anjali Pandey, Isaac Hakim, Sana Mujahid, Aaron C. Daugherty

Leveraging AI From Human Derived Data to Identify Drug Leads and Establish Efficacy for IPF and NASH

Anjali Pandey, Isaac Hakim, Sana Mujahid, Aaron C. Daugherty

IPF Summit v5_FINAL preview

Discovery & Preclinical Validation of Two Therapeutic Leads with Novel MOAs for IPF

Anjali Pandey, Isaac Hakim, Sana Mujahid, Aaron C. Daugherty

Leveraging Drug Discovery with AI

Aaron C. Daugherty

IPF Summit v5_FINAL preview

Discovery & Preclinical Validation of Two Therapeutic Leads with Novel MOAs for IPF

Anjali Pandey, Isaac Hakim, Sana Mujahid, Aaron C. Daugherty
IPF Summit v5_FINAL preview
IPF-Summit-Logo-2020

Discovery & Preclinical Validation of Two Therapeutic Leads with Novel MOAs for IPF

Anjali Pandey, Isaac Hakim, Sana Mujahid, Aaron C. Daugherty

IPF Summit v5_FINAL preview

Discovery & Preclinical Validation of Two Therapeutic Leads with Novel MOAs for IPF

Anjali Pandey, Isaac Hakim, Sana Mujahid, Aaron C. Daugherty

Discovery & Preclinical Validation of Therapeutic Leads with Novel MOAs for CKD

Anjali Pandey, Isaac Hakim, Sana Mujahid, Aaron C. Daugherty
Anjali-Pandey-CKD-Summit-Mar-4-2021_Aria-Rebrand

Discovery & Preclinical Validation of Therapeutic Leads with Novel MOAs for CKD

Anjali Pandey, Isaac Hakim, Sana Mujahid, Aaron C. Daugherty

Preclinical identification and development of small molecule drug discovery leads with novel MOAs for non-alcoholic steatohepatitis (NASH)

Isaac Hakim, Sana Mujahid, Aaron C. Daugherty, Anjali Pandey, Timothy S. Heuer

NASH poster

Preclinical identification and development of small molecule drug discovery leads with novel MOAs for non-alcoholic steatohepatitis (NASH)

Isaac Hakim, Sana Mujahid, Aaron C. Daugherty, Anjali Pandey, Timothy S. Heuer

Computational discovery and preclinical validation of therapeutic leads with novel MOAs for hepatocellular carcinoma and pancreatic ductal adenocarcinoma

Isaac Hakim, Mei-Sze Chua, Wei Wei, Li Ma, Samuel So, Elizabeth Noblin, Sana Mujahid, Aaron C. Daugherty, and Timothy S. Heuer

pancreatic ductal adenocarcinoma

Computational discovery and preclinical validation of therapeutic leads with novel MOAs for hepatocellular carcinoma and pancreatic ductal adenocarcinoma

Isaac Hakim, Mei-Sze Chua, Wei Wei, Li Ma, Samuel So, Elizabeth Noblin, Sana Mujahid, Aaron C. Daugherty, and Timothy S. Heuer

Computational discovery and preclinical validation of therapeutic leads with novel MOAs for systemic lupus erythematosus (SLE)

Hakim, Sana Mujahid, Aaron C Daugherty and Timothy S Heuer

Computational discovery and preclinical validation of therapeutic leads with novel MOAs for systemic lupus erythematosus (SLE)

Hakim, Sana Mujahid, Aaron C Daugherty and Timothy S Heuer

Computational discovery and preclinical validation of therapeutic leads with novel MOAs for systemic lupus erythematosus (SLE)

Isaac Hakim, Sana Mujahid, Aaron C Daugherty and Timothy S Heuer

EULAR SLE Poster

Computational discovery and preclinical validation of therapeutic leads with novel MOAs for systemic lupus erythematosus (SLE)

Isaac Hakim, Sana Mujahid, Aaron C Daugherty and Timothy S Heuer